The company is showcasing new development solutions and advanced digital technologies including its new OSD Express and Steriles Express solutions for drug development.
News|Articles|August 25, 2016
PTSM: Pharmaceutical Technology Sourcing and Management
- PTSM: Pharmaceutical Technology Sourcing and Management-09-07-2016
- Volume 11
- Issue 9
Recipharm Expands Lyophilization Capacity in Italy
Author(s)Pharmaceutical Technology Editors
Recipharm is investing EUR3.7 million (approximately $4.18 million) to increase lyophilization capacity at its Masate facility in Italy.
Advertisement
CDMO Recipharm has
The CDMO offers lyophilization services for both vials and ampoules. The Masate facility specializes in aseptic manufacturing of parenterals.
Recipharm also invested EUR32 million (approximately $36 million) in Wasserburg, Germany in an ongoing project to increase lyophilization capacity at that site.
Source:
Articles in this issue
about 10 years ago
Putting Shelf-Life to the Testabout 10 years ago
The Enzymatic Catalysis Route to Going Greenabout 10 years ago
CMOs Step Up to Test New Bioprocessing Technologyabout 10 years ago
SGS Opens New Facility in Wiesbaden, Germanyabout 10 years ago
CSafe Acquires Kalliboxabout 10 years ago
CordenPharma in France Reports Successful FDA Inspectionabout 10 years ago
Automated Infrared Microscope Effectively Analyzes Micro Samplesabout 10 years ago
Copley Scientific Launches Products for Tablet Dissolution Testingabout 10 years ago
Eppendorf Expands Single-Use Vessel Portfolioabout 10 years ago
PANalytical launches the Empyrean Nano editionAdvertisement
Related to this article
Ron Scarboro, Azurity Pharmaceuticals, explains when formulation robustness justifies added cost and which post-approval quality and supply metrics teams can track.
The winners of the CPHI Pharma Awards 2026 include a neurodegeneration platform, a track-and-trace packaging innovation, a enzymatic mRNA manufacturing technology, and a cell-free enzymatic biomanufacturing platform.
Richard Jaenisch explains why NAMs are compressing drug development faster than AI and what FDA's new nonclinical testing rule means for sponsors.
Hovione's $35M CDC Flex line links spray drying to tablets, designed to eliminate scale-up under FDA Q13 guidance.
This week on PharmTech, Merck diversified its pipeline, USP emphasizes supply chain security, AI systems are examined, and speakers preview their presentations at CPHI Milan and AAPS PharmSci 360.
Capsugel's Bram Baert and Sandrine Picco argue that chasing zero nitrite in pharmaceutical excipients is often impractical and costly. They recommend setting scientifically justified, risk-based limits and consistently staying below them.
Ron Scarboro, Azurity Pharmaceuticals, claims drug reformulation that removes patient barriers must preserve efficacy, urging early cross-functional team alignment.
Advertisement
Advertisement